European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China, Australia, and India Boston (October 22, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today announced that the Eur ...

NEW YORK, Oct. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Allarity Therapeutics, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action by November 12, 2024 [2][3]. Company Overview - Allarity Therapeutics, Inc. is facing scrutiny for allegedly making false and misleading statements regarding its business operations and compliance policies, particularly related to the Dovitinib NDA [3]. - The company has experienced significant leadership changes, including the appointment of interim executives and the termination of its CEO and CFO [4][5][7]. Financial Impact - Following the announcement of leadership changes, Allarity's stock price fell by 19.02% to $1.32 per share on June 30, 2022 [5]. - The stock price further declined by 3.688% to $1.175 per share on August 2, 2022, after the company announced a strategic refocus away from Dovitinib as a monotherapy [6]. - On February 6, 2023, the stock price dropped by 3.8% to $0.228 per share after the company disclosed an SEC investigation [7]. - The stock price fell by 13.37% to $0.486 per share on December 11, 2023, following the termination of the CEO [8]. - On July 22, 2024, the stock price decreased by 2.38% to $0.164 per share after the company received a Wells Notice from the SEC [8]. Legal Proceedings - The class action lawsuit alleges that Allarity and its executives engaged in misconduct that led to increased regulatory scrutiny and potential enforcement actions [3]. - The firm encourages investors who suffered losses exceeding $50,000 between May 17, 2022, and July 19, 2024, to discuss their legal options [1][2].

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities between May 17, 2022, and July 19, 2024, of the upcoming lead plaintiff deadline on November 12, 2024, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Allarity securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 12, 2024 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Allarity made false and misleading statements regarding its drug candidate Dovitinib, overstating its regulatory prospects and engaging in improper conduct related to its new drug application [4]. - The misconduct allegedly led to increased risks of regulatory scrutiny and enforcement actions, resulting in significant legal and reputational harm to Allarity [4]. - Following the announcement of an investigation into Allarity's conduct, the company downplayed the likelihood of enforcement actions, which the lawsuit claims caused investor damages when the truth was revealed [4].

Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about the company's regulatory submissions and the risks associated with them [1][2]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Allarity's securities between May 17, 2022, and July 19, 2024, and encourages them to contact the Schall Law Firm before November 12, 2024 [1]. - The complaint alleges that Allarity and its executives made false and misleading statements regarding the Dovitinib NDA and Dovitinib-DRP PMA, which increased the company's exposure to regulatory scrutiny [2]. - The company is accused of downplaying the likelihood of enforcement actions after an investigation was announced, leading to materially misleading public statements throughout the class period [2]. Group 2: Investor Participation - Investors are invited to join the class action to recover their losses, with the Schall Law Firm specializing in securities class action lawsuits and shareholder rights litigation [3].

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk’s U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarit ...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...